Cargando…

In Vivo Tumor Vasculature Targeting of CuS@MSN Based Theranostic Nanomedicine

[Image: see text] Actively targeted theranostic nanomedicine may be the key for future personalized cancer management. Although numerous types of theranostic nanoparticles have been developed in the past decade for cancer treatment, challenges still exist in the engineering of biocompatible theranos...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Feng, Hong, Hao, Goel, Shreya, Graves, Stephen A., Orbay, Hakan, Ehlerding, Emily B., Shi, Sixiang, Theuer, Charles P., Nickles, Robert J., Cai, Weibo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2015
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4414921/
https://www.ncbi.nlm.nih.gov/pubmed/25843647
http://dx.doi.org/10.1021/nn507241v
_version_ 1782368997848645632
author Chen, Feng
Hong, Hao
Goel, Shreya
Graves, Stephen A.
Orbay, Hakan
Ehlerding, Emily B.
Shi, Sixiang
Theuer, Charles P.
Nickles, Robert J.
Cai, Weibo
author_facet Chen, Feng
Hong, Hao
Goel, Shreya
Graves, Stephen A.
Orbay, Hakan
Ehlerding, Emily B.
Shi, Sixiang
Theuer, Charles P.
Nickles, Robert J.
Cai, Weibo
author_sort Chen, Feng
collection PubMed
description [Image: see text] Actively targeted theranostic nanomedicine may be the key for future personalized cancer management. Although numerous types of theranostic nanoparticles have been developed in the past decade for cancer treatment, challenges still exist in the engineering of biocompatible theranostic nanoparticles with highly specific in vivo tumor targeting capabilities. Here, we report the design, synthesis, surface engineering, and in vivo active vasculature targeting of a new category of theranostic nanoparticle for future cancer management. Water-soluble photothermally sensitive copper sulfide nanoparticles were encapsulated in biocompatible mesoporous silica shells, followed by multistep surface engineering to form the final theranostic nanoparticles. Systematic in vitro targeting, an in vivo long-term toxicity study, photothermal ablation evaluation, in vivo vasculature targeted imaging, biodistribution and histology studies were performed to fully explore the potential of as-developed new theranostic nanoparticles.
format Online
Article
Text
id pubmed-4414921
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-44149212015-12-14 In Vivo Tumor Vasculature Targeting of CuS@MSN Based Theranostic Nanomedicine Chen, Feng Hong, Hao Goel, Shreya Graves, Stephen A. Orbay, Hakan Ehlerding, Emily B. Shi, Sixiang Theuer, Charles P. Nickles, Robert J. Cai, Weibo ACS Nano [Image: see text] Actively targeted theranostic nanomedicine may be the key for future personalized cancer management. Although numerous types of theranostic nanoparticles have been developed in the past decade for cancer treatment, challenges still exist in the engineering of biocompatible theranostic nanoparticles with highly specific in vivo tumor targeting capabilities. Here, we report the design, synthesis, surface engineering, and in vivo active vasculature targeting of a new category of theranostic nanoparticle for future cancer management. Water-soluble photothermally sensitive copper sulfide nanoparticles were encapsulated in biocompatible mesoporous silica shells, followed by multistep surface engineering to form the final theranostic nanoparticles. Systematic in vitro targeting, an in vivo long-term toxicity study, photothermal ablation evaluation, in vivo vasculature targeted imaging, biodistribution and histology studies were performed to fully explore the potential of as-developed new theranostic nanoparticles. American Chemical Society 2015-04-06 2015-04-28 /pmc/articles/PMC4414921/ /pubmed/25843647 http://dx.doi.org/10.1021/nn507241v Text en Copyright © 2015 American Chemical Society This is an open access article published under an ACS AuthorChoice License (http://pubs.acs.org/page/policy/authorchoice_termsofuse.html) , which permits copying and redistribution of the article or any adaptations for non-commercial purposes.
spellingShingle Chen, Feng
Hong, Hao
Goel, Shreya
Graves, Stephen A.
Orbay, Hakan
Ehlerding, Emily B.
Shi, Sixiang
Theuer, Charles P.
Nickles, Robert J.
Cai, Weibo
In Vivo Tumor Vasculature Targeting of CuS@MSN Based Theranostic Nanomedicine
title In Vivo Tumor Vasculature Targeting of CuS@MSN Based Theranostic Nanomedicine
title_full In Vivo Tumor Vasculature Targeting of CuS@MSN Based Theranostic Nanomedicine
title_fullStr In Vivo Tumor Vasculature Targeting of CuS@MSN Based Theranostic Nanomedicine
title_full_unstemmed In Vivo Tumor Vasculature Targeting of CuS@MSN Based Theranostic Nanomedicine
title_short In Vivo Tumor Vasculature Targeting of CuS@MSN Based Theranostic Nanomedicine
title_sort in vivo tumor vasculature targeting of cus@msn based theranostic nanomedicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4414921/
https://www.ncbi.nlm.nih.gov/pubmed/25843647
http://dx.doi.org/10.1021/nn507241v
work_keys_str_mv AT chenfeng invivotumorvasculaturetargetingofcusmsnbasedtheranosticnanomedicine
AT honghao invivotumorvasculaturetargetingofcusmsnbasedtheranosticnanomedicine
AT goelshreya invivotumorvasculaturetargetingofcusmsnbasedtheranosticnanomedicine
AT gravesstephena invivotumorvasculaturetargetingofcusmsnbasedtheranosticnanomedicine
AT orbayhakan invivotumorvasculaturetargetingofcusmsnbasedtheranosticnanomedicine
AT ehlerdingemilyb invivotumorvasculaturetargetingofcusmsnbasedtheranosticnanomedicine
AT shisixiang invivotumorvasculaturetargetingofcusmsnbasedtheranosticnanomedicine
AT theuercharlesp invivotumorvasculaturetargetingofcusmsnbasedtheranosticnanomedicine
AT nicklesrobertj invivotumorvasculaturetargetingofcusmsnbasedtheranosticnanomedicine
AT caiweibo invivotumorvasculaturetargetingofcusmsnbasedtheranosticnanomedicine